Stock Research for OMER

OMER

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

OMER Stock Chart & Research Data

The OMER chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OMER chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


OMER Due diligence Resources & Stock Charts

The OMER stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View OMER Detailed Price Forecast - CNN Money CNN View OMER Detailed Summary - Google Finance
Yahoo View OMER Detailed Summary - Yahoo! Finance Zacks View OMER Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View OMER Trends & Analysis - Trade-Ideas Barrons View OMER Major Holders - Barrons
NASDAQ View OMER Call Transcripts - NASDAQ Seeking View OMER Breaking News & Analysis - Seeking Alpha
Spotlight View OMER Annual Report - CompanySpotlight.com OTC Report View OMER OTC Short Report - OTCShortReport.com
TradeKing View OMER Fundamentals - TradeKing Charts View OMER SEC Filings - Bar Chart
WSJ View Historical Prices for OMER - The WSJ Morningstar View Performance/Total Return for OMER - Morningstar
MarketWatch View the Analyst Estimates for OMER - MarketWatch CNBC View the Earnings History for OMER - CNBC
StockMarketWatch View the OMER Earnings - StockMarketWatch MacroAxis View OMER Buy or Sell Recommendations - MacroAxis
Bullish View the OMER Bullish Patterns - American Bulls Short Pains View OMER Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View OMER Stock Mentions - StockTwits PennyStocks View OMER Stock Mentions - PennyStockTweets
Twitter View OMER Stock Mentions - Twitter Invest Hub View OMER Investment Forum News - Investor Hub
Yahoo View OMER Stock Mentions - Yahoo! Message Board Seeking Alpha View OMER Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for OMER - SECform4.com Insider Cow View Insider Transactions for OMER - Insider Cow
CNBC View OMER Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for OMER - OTC Markets
Yahoo View Insider Transactions for OMER - Yahoo! Finance NASDAQ View Institutional Holdings for OMER - NASDAQ


Stock Charts

FinViz View OMER Stock Insight & Charts - FinViz.com StockCharts View OMER Investment Charts - StockCharts.com
BarChart View OMER Stock Overview & Charts - BarChart Trading View View OMER User Generated Charts - Trading View


Latest Financial News for OMER

FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Posted on Thursday April 26, 2018

Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to OMS721 for the treatment of patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), specifically those patients who have persistent TMA despite modification of immunosuppressive therapy. This is the second breakthrough therapy drug designation for OMS721, which last year received the designation from FDA for the treatment of Immunoglobulin A (IgA) nephropathy.


Research Report Identifies T. Rowe Price Group, Omeros, Old Dominion Freight Line, Dillard's, BGC Partners, and Rexnord with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Posted on Thursday April 19, 2018

NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...


Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting
Posted on Thursday April 19, 2018

Omeros Corporation  announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA® 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting held in Washington, D.C., April 13-17, 2018.


Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting
Posted on Friday April 13, 2018

Omeros Corporation today announced that the results of four studies directed to the benefits of OMIDRIA across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive Surgery Congress in Washington, D.C., April 13-17, 2018.


Enter a stock symbol to view the stock details.